Emergent BioSolutions Inc. (EBS) Earnings Call Analysis
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Emergent BioSolutions (EBS) Q1 2026: International MCM Revenue Climbs to 37%, Sharpening Margin Profile
May 01, 2026
-
EBS Q4 2025: Net Leverage Cut to 1.9x as Cash Flow Surges and Margin Expands
February 27, 2026
-
EBS Q3 2025: International MCM Sales Jump to 34%, Fueling Margin Expansion
October 29, 2025
-
Emergent BioSolutions (EBS) Q2 2025: Net Leverage Drops to 1.9x as MCM and Narcan Rebound
August 06, 2025
-
Emergent BioSolutions (EBS) Q1 2025: Net Leverage Cut to 2.8x as Turnaround Drives Margin Expansion
July 04, 2025